Efficacy of intravenous Ig in patients with CIDP (the secondary measures)
| Week 1–28 (n=49) | Week 29–52 (n=38)* | ||||
| Week 1 | Week 4 | Week 28 | Week 28* | Week 52 | |
| INCAT score | 4.1 (1.4) | 3.1 (1.8) | 2.8 (1.9)† | 2.2 (1.2) | 1.9 (1.3) |
| ISS score | 7.4 (4.2) | 6.4 (4.5) | 4.9 (3.8)† | 4.3 (3.4) | 4.4 (3.5) |
| Grip strength (kPa) | |||||
| Dominant hand | 37.1 (25.0) | 46.4 (23.9) | 50.1 (27.2)† | 54.2 (24.9) | 57.1 (26.8) |
| Non-dominant hand | 36.6 (22.5) | 46.5 (23.1) | 49.4 (26.1)† | 53.1 (24.0) | 55.8 (25.7) |
| Total MRC score | 50.7±7.3 | 53.8±7.8 | 54.5±8.4 | 57.0±4.5 | 56.9±4.9 |
| CMAP amplitude (mV) (most affected nerve) | 1.1 (1.8)‡ | 1.5 (2.5)§ | 1.8 (2.1)¶ | 1.8 (2.1)¶ | 1.7 (2.2)** |
| Serum IgG (mg/dL) | 1210 (357) | 2058 (369)†† | 1936 (369)‡‡ | 1936 (369)‡‡ | 2012 (341)¶ |
Data are shown as mean (SD).
*Only responders at week 28 were included.
†p<0.01, compared with a baseline value.
‡n=46.
§n=45.
¶n=34.
**n=32.
††n=48.
‡‡n=38.
CMAP, compound muscle action potential; INCAT, Inflammatory Neuropathy Cause and Treatment; ISS, INCAT sensory sum; MRC, Medical Research Council.